Background Patients with resistant hypertension are at a high risk for developing serious cardiovascular events and renal complications. Catheter-based renal denervation (RDN) is a procedure with the potential to normalize systolic blood pressure (SBP).
Introduction
Hypertension is a commonly diagnosed condition in the adult population, with a reported prevalence of approximately 30 % in the UK [1] . The general definition for hypertension in patients is having systolic blood pressure (SBP) and diastolic blood pressure (DBP) remaining persistently above the normal ranges of 100-140 and 60-90 mmHg, respectively [2, 3] . Despite active treatment with three alternative anti-hypertensive pharmacological treatments (angiotensin-converting enzyme inhibitor [ACE] , a calcium channel blocker, and a thiazide-type diuretic at maximum recommended or tolerated dose level), approximately 10-20 % of patients progress to develop resistant hypertension, with SBP and DPB readings remaining above target, and therefore meet the criteria for resistant hypertension [4, 5] . This is estimated to equate to approximately 0.5 million patients in the UK with inadequately controlled blood pressure [6] . The presence of resistant hypertension puts patients at a particularly increased risk for a range of serious cardiovascular disease and renal complications, including acute stroke, transient ischemic attacks, myocardial infarction (MI), heart failure (HF), end-stage renal disease (ESRD), angina pectoris (AP)/coronary heart disease (CHD), and peripheral arterial disease [7] .
Catheter-based renal denervation (RDN) is a procedurebased treatment that has been shown to substantially reduce blood pressure, and has the potential to normalize blood pressure in a meaningful subset of resistant hypertensive patients. The procedure disrupts afferent and efferent nerves using radio frequency ablation, reducing the sympathetic drive and therefore constriction of blood vessels, resulting in lower blood pressure [8] . The Symplicity HTN-2 trial randomized 106 patients to either RDN plus standard of care (SoC) or SoC alone based on three or more antihypertensive medications [9] . Patients enrolled in the Symplicity HTN-2 trial had a mean baseline SBP of 178 ± 18 mmHg. The trial reported a 6-month mean decrease in SBP of 32 ± 23 mmHg for patients treated with RDN plus SoC, compared with a mean increase in SBP of 1 ± 21 mmHg for patients treated with SoC alone. A related single-armed study with a follow-up of 24 months found that the reduction in SBP following RDN therapy persisted for the full duration of the study, demonstrating a sustained clinical benefit from RDN [10] .
A US-based economic model ('the Wing Tech model') published in the Journal of the American College of Cardiology in 2012 has been used to explore the overall cost effectiveness of RDN, using the expected short-term and sustained improvements in blood pressure as surrogate endpoints to predict longer-term reductions in risks of cardiovascular and renal complications [11] . The model was developed in TreeAge and reported the cost and health-related quality of life (HRQoL) benefits of RDN relative to SoC, as defined in the Symplicity HTN-2 trial [9] . The model predicted substantial reductions in lifetime event risks for patients treated with RDN plus SoC, compared with those treated with SoC, in terms of stroke (RR = 0.83), MI (RR = 0.85); CHD (RR = 0.90), HF (RR = 0.92), and ESRD (RR = 0.81) [11] . Overall median survival was reported as 18.4 years for RDN compared with 17.1 years for SoC. The discounted lifetime incremental cost-effectiveness ratio (ICER) was $3,071 per quality-adjusted life-year (QALY), suggesting RDN is a highly cost-effective intervention for the treatment of resistant hypertension [8, 9, 11] .
In the UK, the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium formally evaluate new health technologies as a prelude to issuing guidance on their use in the National Health Service. A critical step in these evaluations is establishing the overall value of a new treatment over a time horizon long enough to capture the key additional health benefits and overall cost. This paper reports an economic model-based, patient lifetime evaluation of the RDN therapy for resistant hypertension, based on UK-specific data covering the expected cost of providing RDN, the cost and HRQoL impacts from cardiovascular events and renal complications, and mortality statistics. The overall objective of the study was to estimate the cost effectiveness of RDN for
Key Points for Decision Makers
Catheter-based renal denervation (RDN) therapy is a highly cost-effective treatment for patients with resistant hypertension using a conventional costeffectiveness threshold of £20,000-£30,000 per quality-adjusted life-year.
Treatment with RDN compared with standard of care (SoC) reduces both morbidity and mortality, with patients having fewer cardiovascular events because of the sustained reduction in systolic blood pressure.
The reduction in cardiovascular events from treatment with RDN, particularly strokes, results in substantial cost offsets compared with SoC.
Scenario analyses have shown treatment with RDN is cost effective in the long term.
RDN is a safe and effective procedure-based alternative for a patient population that is resistant to pharmacological interventions and has few alternative treatment options.
patients in the UK with diagnosed resistant hypertension, expressed as a standard cost per QALY ratio.
Methods

Model Structure
The UK RDN model is based on the same underlying health-state structure as used in the original US-based Wing Tech model (Fig. 1) . The structure represents the following seven key clinical events; acute stroke, ESRD, HF, AP/CHD, MI, cardiovascular-related death, and general (non-cardiovascular) mortality. Overall, the model has 34 uniquely defined health states, which are used to characterize disease progression, including health states for post-stroke and post-MI. The health-state structure also allows patients to be categorized as having experienced more than one type of event (for example, patients in the model can experience an MI event after previously developing ESRD, which is represented in the model as an ESRD-MI health state). This approach, using a series of sub-states (as per the Wing Tech model), was adopted to incorporate competing risks and to allow the risks of subsequent events to vary related to the occurrence of prior cardiovascular and renal events. As mortality rate and HRQoL are known to be highly time dependent over the first 6 months after an acute MI or an acute stroke event, the model uses a series of additional time-dependent tunnel states representing the post-MI and post-stroke time periods. The model is therefore most appropriately described as a modified Markov health-state structure, with event history-based transition probabilities.
Time Horizon and Perspective
In the base case analysis, the time horizon was modeled to cover a patient's lifetime, although the model has the flexibility to report at a shorter 10-year time horizon. A 1-month cycle length was used to consider movement of patients between health states. The model used a standard set of general mortality rates for the UK, and applied a maximum patient age of 100 years [12] . In line with the NICE reference case, the key outcomes of the model include total direct costs, life-years, and QALYs; the costs and QALY outcomes were discounted at 3.5 % per annum. The model was built from a UK single health-payer perspective, covering direct costs of health and social care costs.
Patient Population
The patient population considered in the model is based on the inclusion criteria of the Symplicity HTN-2 trial (Table 1) , which was the largest randomized controlled trial in RDN at the time of model development. In the study, patients had an average age of 58 years, 43 % were female, 16 % were smokers, and 34 % had an existing diagnosis of diabetes mellitus [9] . Patients had a reported baseline SBP of 178 mmHg (95 % confidence interval 175-182 mmHg), and had an average of five prior medications for their resistant hypertension at baseline. As in Fig. 1 Model structure. Non-cardiovascular death is applied at each cycle based on the general mortality rate (for hypertension patients) and modeled ESRD mortality (ESRD state). Cardiovascular death is applied at each cycle based on the published data for CHD, stroke, MI, and mortality. At each cycle of the model patients can either remain in their current health state or experience a new CV or non-CV event or death and move to a new state. CHD coronary heart disease, ESRD end-stage renal disease, HF heart failure, MI myocardial infarction. Z value is a multiplication value used for transition probabilities in the sensitivity analysis [11, 18, 20] ESRD mortality Age-stratified regression (0.24-1.27 % per month) ERA-EDTA Registry [21] AP/CHD mortality Age-stratified regression (0.24-10.6 % per month) [22] HRQL/utility weights Stroke utility 0.629 [23] MI utility (months 1-6) 0.760 [23, 24] MI utility (months 7?) 0.880 [7] HF utility 0.683 [25] AP/CHD utility 0.767 [26] Unstable AP/CHD 0.770 [24, 26] Stable AP/CHD 0.808 [23, 26] ESRD utility 0.72 [27] Hypertension utility 1.00 [23, 28] Costs Stroke cost Acute stroke = £10,726 (month 1); poststroke = £191/month Anti-hypertensive drug cost £5.80/month (including 1 GP visit per year) BNF63 ? PSSRU unit costs [31, 32] RDN cost £4,500/procedure Data on file: Medtronic plc (2013)
AP angina pectoris, BNF British National Formulary, BT blood and transplant, CHD coronary heart disease, DM diabetes mellitus, ERA-EDTA European Renal Association-European Dialysis and Transplantation Association, ESRD end-stage renal disease, GP general practitioner, HDL high-density lipid, HF heart failure, HR hazard ratio, HRG Healthcare Research Group, HRQL health-related quality of life, LDL low-density lipids, MI myocardial infarction, NHS National Health Service, PSSRU Personal Social Services Research Unit, RDN renal denervation, RR relative risk, SBP systolic blood pressure, w/o without the original Wing Tech model, to maximize the predictive validity of the multivariate risk equations used to simulate significant clinical events in the model, we assumed patients had no prior cardiovascular events, manifest CHD, or evidence of underlying ESRD.
Clinical Inputs
Risk Equations and Systolic Blood Pressure Reduction
The UK model used the same approach as undertaken in the original US model to estimate the risk of the different cardiovascular and non-cardiovascular events. Multivariate risk equations from large-scale cohort studies, particularly the Framingham Heart Study, have been used to calculate the underlying transition probabilities based on a range of patient baseline characteristics including, but not limited to; age, sex, smoking status, high-density lipids, low-density lipids, diabetes, and the presence of other cardiovascular conditions (Table 1 ) [9, 11] . Many of these multivariate risk equations also identified SBP as a significant predictor of the risk of experiencing a cardiovascular event or ESRD [33] [34] [35] . Those patients allocated to the SoC arm were assumed to have a continuing SBP of 178 mmHg, based on the baseline measure for patients enrolled in the Symplicity HTN-2 trial [9] . The patients treated with RDN were assigned a lower mean SBP, with a reduction of 32 mmHg applied at 6 months (in line with Symplicity HTN-2 trial data [9] ), and were therefore associated with lower risks of experiencing the modeled cardiovascular clinical endpoints. In the base-case analysis, the treatment effect of RDN therapy was assumed to be maintained and continued over time.
Mortality Data
Mortality risks were applied in the model in two specific ways, general mortality and disease-specific mortality (Table 1) . A standard set of age/sex stratified 'all-cause' mortality risks were applied to all patients for every cycle over the time horizon of the model [12] . Disease-specific mortality was applied as either modeled absolute risks from published regression equations or as additional relative risks to the underlying mortality data [11] . Increased risks of mortality were linked to: presence of ESRD [21] , presence of AP/CHD [22] , the first 30-day MI period [17] [18] [19] , post-MI state [17] [18] [19] , the first 30-day stroke period [13] , post-stroke state [11] , stroke post-MI state [15] , stroke post-HF state [14, 16] , and HF state [11, 18, 20] . Where patients experienced subsequent clinical events, the highest of the associated mortality rates was applied for each cycle of the model.
Costs
The model used a series of cost data representing the typical clinical management of patients during time spent in chronic health states (such as ESRD, HF, post-stroke, and post-MI), and the healthcare resource impact of acute clinical events (such as stroke or MI). A set of standard National Health Service reference costs (based on 2012 values) were used for the majority of cost data, representing the typical average Healthcare Research Group (HRG)-based direct cost for providing hospital-based care in the UK (Table 1 ) [28] . Additional UK-relevant cost data were identified through a systematic literature search ( Table 1) . The model did not consider the wider societal cost as a result of lost productivity or potential carer costs. Drug costs for anti-hypertensive pharmacological treatments, such as an ACE inhibitor, a calcium channel blocker, and a thiazide-type diuretic, were based on standard British National Formulary costs for the UK [31] . The cost of the RDN procedure of £4,500 per patient was taken from data on file provided by the manufacturer and captures both the HRG code associated with treatment and the cost of equipment.
Utilities
The model assigned a series of utility weights to health states represented within the structure; based on stroke; MI, HF, AP/CHD (stable and unstable), and ESRD (Table 1) . The values were identified through a systematic review of the literature, a published economic model of statin treatment [23] , and utility data used in UK guidelines for the clinical management of hypertension [4] . The search strategy included utility values derived using the EQ-5D method, in line with recommendations from UK health technology assessment bodies [15] . The utility weights are used in the model to quality-adjust time spent in alternative levels of HRQoL, to calculate QALY values for patients with and without an RDN procedure. A utility weight of 0.629 was assigned to a stroke event, taken from a UK health technology assessment report, which considered the economic value of statins in the prevention of coronary events [23] . The same technology assessment provided previously published estimates of utility for stable and unstable AP/CHD (0.808 and 0.770, respectively) [23, 24, 26] . The utility for patients immediately surviving an MI event was set at 0.760 based on data from a randomized study evaluating treatment options for chest pain [23, 24] . For the ESRD state, a utility weight of 0.72 was identified from a published HRQoL review for patients with chronic renal disease [27] . Finally, for the HF state, a utility weight of 0.683 was applied [25] . All utility values were adjusted for the effects of age using a utility multiplier derived from the UK population norms for EQ-5D [36] .
A baseline assumption was taken that the underlying hypertension caused no decrease in overall HRQL when no acute or chronic event was present. We therefore assigned a utility of 1 for all patients prior to a cardiovascular event or renal complication.
Scenario Analysis
In the base-case analysis, the reduction in SBP for those receiving RDN plus SoC was modeled as 32 mmHg, taken from the 6-month Symplicity HTN-2 trial data [9] ). However, recent preliminary data published from the first randomized, sham-controlled trial of RDN therapy (HTN-3) [37] indicated a reduction in the SBP from baseline of 14.13 mmHg (±29.93) for patients receiving RDN plus SoC and 11.74 mmHg (±25.94) for those on the sham arm [38] . A scenario was therefore considered using the reduced treatment effect of 14.13 mmHg in the RDN plus SoC arm compared with no change on the SoC-alone arm. This was deemed a more relevant comparison to real-world practice SoC, as patients will not be offered a sham procedure in clinical practice.
An additional scenario was also considered around the duration of the RDN treatment effect. The SBP reduction used in the base case was assumed to be a sustained treatment effect from the RDN procedure. However, there is a degree of uncertainty around this assumption given the lack of longterm data available. The longest follow-up data available are from the Symplicity HTN-1 trial, which indicated that the mean reduction in SBP treatment effect for RDN is likely to increase over time with a mean SBP at 36 months of 142.6 mmHg (standard deviation ±17.7) compared with 145.4 mmHg (standard deviation ±21.7) at 24 months [39] . However, these data are still relatively immature for a chronic condition and are from a single-arm phase II trial. A second scenario was therefore considered whereby a retreatment with RDN every 10 years is required to sustain the clinical effect assumed in the base case.
Sensitivity Analysis
A range of sensitivity analyses were undertaken to assess the level of parameter uncertainty in the base-case ICER values. A set of deterministic one-way sensitivity analyses were performed to assess the robustness of the model's base case analysis to independent changes in individual parameter values. The sensitivity analyses used extreme values for the parameters, based on 95 % confidence intervals to define upper and lower bounds of each parameter, which were then used in the model to calculate variation in cost per QALY values. Most input variables were assumed to have a normal distribution with the exception of costs (gamma), and any inputs bounded between 0 and 1 such as percentages and utility values (beta) (see online resource; Table 6 ). The individual parameters having the greatest observed effect on the ICER were plotted in the form of a tornado diagram. In addition, a standard probabilistic sensitivity analysis (PSA) was also undertaken varying parameter values concurrently. Monte Carlo simulation methods were used to iteratively sample from a set of credible parameter ranges and distributions assigned to each model parameter. The PSA was run for 5,000 iterations and sampled for 156 parameters. The results of the PSA are reported as a costeffectiveness acceptability curve, which shows the probability of RDN being cost effective over a variety of willingness-to-pay threshold values.
Results
Base-Case Analyses
The base-case results indicate that treatment with RDN therapy results in an increase in QALYs over a patient's lifetime compared with SoC alone (12.77 vs. 12.16 QALY/ patient discounted; 18.33 vs. 17.14 undiscounted) ( Table 2 ). This additional health benefit is derived from reductions in the risk for cardiovascular events, with the greatest savings coming from avoided acute stroke events and AP/CHD. The additional cost of providing RDN (estimated at £4,500 per procedure) is off-set by cost savings owing to reduced cardiovascular events; savings from avoided acute stroke events represents the majority at £2,000 of avoided costs per patient lifetime (Table 3) . Overall, the additional lifetime cost for patients undergoing RDN £2,961 discounted and is £2,288 undiscounted (Tables 2 and 3 ). Reflecting these figures in a cost-effectiveness calculation, the overall cost per QALY for RDN is estimated at £4,805 based on UK annual discount rates of 3.5 % applied to both costs and health benefits, which is substantially below the NICE cost-effectiveness threshold of £20,000 per QALY gained [40] .
Scenario Analyses
Under the first scenario, based on the HTN-3 data, results indicate that RDN therapy is cost effective at conventional threshold levels used in the UK at the lower treatment effect of 14.26 mmHg. Furthermore, RDN is cost effective at a threshold value of £30,000 up to a reduction in SBP from baseline of approximately 10 mmHg; well below any published estimation of the treatment effect from RDN therapy.
For the second scenario analysis, the model was re-run based on the assumption that the RDN procedure would need to be repeated every 10 years to maintain health benefits. Under this assumption, the discounted ICER for RDN increased to £11,682 (Table 4) . Again, this level of ICER remains comfortably below the NICE cost-effectiveness thresholds.
Sensitivity Analyses
The upper and lower parameter value ranges were explored in the sensitivity analyses. Details of assumptions for the underlying distributions and measures of variance/standard error on the base-case values are presented in Table 5 . The results of the deterministic sensitivity analysis are presented in Table 5 and Fig. 2 , which shows the variation in the cost per QALY gained when using different parameter values. Under these sensitivity analyses, varying values independently resulted in ICERs well below the generally accepted thresholds of £20,000 per QALY ( Table 5 ).
The expected reduction in SBP associated with RDN therapy has by far the greatest effect on the level of ICER values, in the range of £3,068-£7,281 for the cost per QALY. This result is in line with the original findings by Geisler and colleagues [11] in the US model, and reflects the level of uncertainty associated with this parameter. The result is expected as this variable captures the primary efficacy of the intervention, and is an important explanatory variable in many of the models underlying risk equations for cardiovascular events and renal complications.
In addition, the cost of RDN therapy is an influential variable as it is a substantial upfront cost incurred by all patients in the RDN treatment arm (Table 5 ). Baseline SBP also has a substantial effect on the overall ICER for RDN, causing it to vary from £4,207 to £5,546. Again, this result is expected and in line with the effect observed with the reduction in SBP, as this variable is the basis for defining the proportional SBP difference between the arms, and thus the relative efficacy of RDN therapy overall. The levels of uncertainty in all other parameters have only minor effects on the overall ICER (Table 5 ).
When the model was run in a PSA, considering concurrently the uncertainty in the model and drawing parameter values from the parametric distributions over 5,000 iterations, the ICER remained well below the £20,000 threshold (Fig. 3) . The corresponding cost-effectiveness acceptability curve clearly demonstrates this, with the most likely ICER value (the probabilistic value) reported at £4,647 (Fig. 4) .
Discussion
The UK RDN model is based on a previously validated Markov health-state model published in 2012 [11] , which is used in the USA to evaluate the cost effectiveness of LY life-year, QALY quality-adjusted life-year, RDN renal denervation, SoC standard of care AP angina pectoris, CHD coronary heart disease, ESRD end-stage renal disease, HF heart failure, HRQoL health-related quality of life, MI myocardial infarction, RDN renal denervation, SoC standard of care RDN in patients with diagnosed resistant hypertension. The model was reprogrammed in Microsoft Ò Excel (Microsoft, Redmond, WA, USA) and updated with UK cost, utilities, and mortality data. The results of this model demonstrate that, compared with current SoC, RDN is a cost-effective treatment of resistant hypertension when considered against the conventional willingness-to-pay thresholds adopted as part of the NICE single technology appraisal process in the UK [40] . The deterministic results from the base case suggest an ICER of £4,805 per QALY. A full set of deterministic sensitivity analysis suggests that only changes in the cost of RDN (currently estimated at £4,500), the baseline SBP, and substantially lower reductions in SBP (well below that seen in the Symplicity HTN-2 trial [9] ) could increase the ICER significantly. However, even in these cases, the ICER remained in the £3,000-£8,000 per QALY range. Finally, an overall assessment of the impact of parameter uncertainty, through the PSA analysis, provides further reassurance that the cost effectiveness of RDN is a robust finding.
However, there is some uncertainty around the duration and size of the treatment effect from RDN therapy given the lack of long-term data and recent results from the HTN-3 clinical trial [37] . HTN-3 is the first randomized, singleblind, phase III study and recently presented the results showing a reduction of 14.14 mmHg in the RDN plus SoC arm compared with 11.23 mmHg in the sham arm. It was the first trial on RDN therapy to not reach the primary endpoint, though it is thought a variety of confounding factors may have contributed to these unexpected results including: increased drug adherence as a result of trial design, CV cardiovascular, DM diabetes mellitus, HF heart failure, ICER incremental cost-effectiveness ratio, MI myocardial infarction, RDN renal denervation, SBP systolic blood pressure
In some cases, the lower bound parameter value is a positive effect in reducing the ICER value (e.g., cost of acute stroke)
greater number of trial sites leading to procedural variability, differences in the requirement for maximum tolerated doses, and differences in case proctoring.
Results from the HTN-3 clinical trial were incorporated into the model through scenario analysis, using 14.23 mmHg as shown in the trial for patients receiving Despite this uncertainty, the reduction in SBP shown in HTN-3 is a significant reduction compared with most statin therapies, which typically give a reduction in SBP of around 1.45-2.2 mmHg [41] [42] [43] . Furthermore, results from a scenario analysis show RDN remains below conventional cost-effectiveness threshold levels used in the UK when assuming a reduction in baseline SBP of 14.23 mmHg. Scenario analysis investigating the cost effectiveness of retreatment every 10 years also indicated RDN therapy was highly cost effective with an ICER of £14,312.
However, the latest long-term follow-up data from the single-armed Symplicity HTN-1 trial suggest a degree of delayed response may be expected in patients who do not show clear improvements in their SBP immediately after RDN. Results from the 36-month follow-up of Symplicity HTN-1 have shown an increase in the response rate with 93 % of patients having achieved a drop in SBP of at least 10 mmHg, compared with 83 % at 24 months and 85 % at 12 months [39] . This trend suggests retreatment with RDN therapy and the preliminary results given in HTN-3 may not be representative of the cost effectiveness of RDN therapy over a patient's lifetime.
In contrast to the US model, we found that, although RDN resulted in some significant cost savings through a reduction in the frequency of acute events and time spent in chronic cardiovascular and renal health states, RDN did not result in overall cost savings once the procedure costs were included. This difference between the models is because of the higher estimates of healthcare costs in the USA for the events represented; this is a common finding in adapted economic models. The UK model clearly confirms the ability of RDN to reduce time spent in acute and chronic health states, through reduced SBP, and that it does so within conventional cost-effectiveness thresholds.
The internal validity of the model was verified by ensuring results matched exactly those from the US model, prior to inclusion of UK data. External validity of the US model (from which the UK model was derived) was assessed in several ways including a comparison of results with those from the NICE hypertension model, as well as comparing model projections to event rates reported for the placebo arms of several large-scale, hypertension randomized controlled trials. This shows that the UK RDN model fully replicates the original model, and suggests that the underlying model structure is appropriate.
The methodology used in the design of this model required extrapolation well beyond the length of the available trial data. Consequently, the results are heavily reliant on the predictive equations used in the model. In particular, the Framingham risk equation was used to estimate the probabilities of all cardiovascular events (except for MI where the PROCAM risk equation was used). There is some evidence to suggest that the Framingham risk equations, which are based on a US population, over-estimate the risk of cardiovascular events [44] . The disparity seen may represent actual differences in the levels of CHD risk in the Framingham population and the British population, or may be the result of the improved care and treatment for patients with hypertension since the risk equations were developed. In addition, the hypertensive population under consideration in this model has an increased risk of cardiovascular events compared with the general UK population. The true predictive power of the Framingham risk equations in this population is therefore unknown [44] . While the limitations of the Framingham equations are recognized, a recent literature review we conducted did not reveal any improvements on the Framingham equations for the UK population. Therefore, we consider this approach to be the most appropriate at this time.
Non-adherence and drug intolerance are also seen to play a clear role in uncontrolled blood pressure and have similar associated negative health impacts, but are generally seen to fall outside of a strict definition of resistant hypertension [45] . Although there is the potential to increase the number of concurrent pharmacological therapies in patients with poorly controlled or uncontrolled blood pressure, there remains a lack of published systematic clinical assessments of three or four drug combinations [45] .
Conclusions
Resistant hypertension is a chronic condition that has a range of serious complications, which can reduce life expectancy and affect quality of life. These are driven largely by the inability to control SBP to within the normal range of 100-140 mmHg. The standard anti-hypertensive therapies recommended in current clinical guidelines provide little hope for improvement in this patient group. RDN is a clinically proven procedure that has the potential to offer patients a meaningful and cost-effective alternative for achieving SBP control, where traditional combination, anti-hypertensive drug-based strategies have been proven to be ineffective.
